araag2/HINT huggingface dataset:
Clinical trial NCT02182778 (phase 3, status: completed)
Conditions: biliary tract cancer
ICD codes: C24.9, C24.8
Drugs: gemcitabine/cisplatin, gemcitabine/cisplatin /s-1
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with cytologically or histologically proved biliary tract cancer

          2. age >=20 years

          3. Performance Status (PS) 0-2

          4. No prior history of chemotherapy or radiotherapy.

          5. Adequate bone marrow function (neutrophil count >=1,500/mm3, and platelet count
             >=100,000/mm3), liver function (total bilirubin >=3 mg/dL and AST/ALT >=150 IU/L), and
             renal function (creatinine clearance >=45 mL/min)

          6. Adequate oral intake

          7. Provided written informed consent -

        Exclusion Criteria:

          1. Patients with interstitial pneumonia or pulmonary fibrosis

          2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a
             new onset of myocardial infarction within 3 months

          3. Patients with severe active infection

          4. Patients with moderate or marked pleural effusion or ascites necessitating drainage

          5. Patients with a history of severe drug allergy

          6. Patients with other serious comorbid disease

          7. Patients who are pregnant or lactating, or have an intention to get pregnant

          8. Patients with mental disease

          9. Patients who are judged inappropriate for the entry into the study by the principle
             doctor

             -
Clinical trial NCT02184195 (phase 3, status: active, not recruiting)
Conditions: germline brca1/2 mutations and, metastatic adenocarcinoma of the pancreas
ICD codes: J84.83, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: olaparib, olaparib, placebo, placebo
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria

          -  Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial
             chemotherapy for metastatic disease and without evidence of disease progression on
             treatment

          -  Patients with measurable disease and/or non-measurable or no evidence of disease
             assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in
             this study.

          -  Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or
             suspected deleterious

          -  Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or
             oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16
             weeks of continuous platinum treatment and have no evidence of progression based on
             investigator's opinion.

          -  Patients who have received platinum as potentially curative treatment for a prior
             cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer
             are eligible provided at least 12 months have elapsed between the last dose of
             platinum-based treatment and initiation of the platinum-based chemotherapy for
             metastatic pancreas cancer.

        Major Exclusion Criteria:

          -  gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg,
             "Variants of uncertain clinical significance" or "Variant of unknown significance" or
             "Variant, favour polymorphism" or "benign polymorphism" etc.)

          -  Progression of tumour between start of first line platinum based chemotherapy for
             metastatic pancreas cancer and randomisation.

          -  Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle

             1 Day 1 is not permitted.

          -  Exposure to an investigational product within 30 days or 5 half lives (whichever is
             longer) prior to randomisation

          -  Any previous treatment with a PARP inhibitor, including Olaparib
Clinical trial NCT02186171 (phase 3, status: completed)
Conditions: osteoporosis in men
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be ambulatory male subjects ≥ 55 years to ≤ 90 years of age

          -  Must have a BMD T score ≤ -2.50 at the spine or hip, or BMD T score ≤ -1.50 at the
             spine or hip and a history of fragility nonvertebral fracture or vertebral fracture.

        Exclusion Criteria:

          -  A BMD T score ≤ -3.50 at the hip,

          -  History of hip fracture

          -  Severe metabolic bone diseases

          -  Significant laboratory abnormalities

          -  Recent treatment with agents affecting bone metabolism
Clinical trial NCT02186873 (phase 3, status: completed)
Conditions: ankylosing spondylitis
ICD codes: M08.1, M45.6, M45.2, M45.3, M45.4, M45.5, M45.7
Drugs: placebo, golimumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with diagnosis of definite ankylosing spondylitis for at least 3 months
             based on modified New York radiographic and clinical criteria

          -  Participants with symptoms of active disease at screening and at baseline

          -  Participant has either an inadequate response to at least 2 non-steroidal
             anti-inflammatory drugs (NSAID) over a 4 week period in total with maximal recommended
             doses of NSAIDs, or is unable to receive a full 4 weeks of maximal NSAID therapy
             because of intolerance, toxicity, or contraindications to NSAIDs

          -  Participants with C- reactive protein (CRP) level of greater than or equal to (>=) 0.3
             milligram per deciliter (mg/dL) at screening

          -  Additional protocol-defined inclusion criteria apply

        Exclusion Criteria:

          -  Participant with other inflammatory diseases that might confound the evaluations of
             benefit from the golimumab therapy

          -  Pregnant or lactating females

          -  Participants with chest radiograph within 3 months prior to the first administration
             of study agent that shows an abnormality suggestive of a malignancy or current active
             infection, including tuberculosis

          -  Participants who had a serious infection (including but not limited to, hepatitis,
             pneumonia, sepsis, or pyelonephritis), or have been hospitalized for an infection, or
             have been treated with intravenous (IV) antibiotics for an infection within 2 months
             prior to first administration of study agent

          -  Additional protocol-defined exclusion criteria apply
Clinical trial NCT02187809 (phase 3, status: terminated)
Conditions: dravet syndrome
ICD codes: G40.833, G40.834
Drugs: clobazam
SMILES: CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
Reason stopped: 
    the study was terminated due to recruitment challenges
  
Eligibility criteria:

        The inclusion and exclusion criteria for the patients who participated in lead-in Study
        14362A will be transferred from the 14362A study and for the patients who did not
        participate in lead-in Study 14362A the inclusion/exclusion is separately listed below.

        Inclusion Criteria:

          1. The patient has a diagnosis of Dravet Syndrome supported by:

               1. onset of seizures in the first year of life

               2. history of fever-induced prolonged seizures as determined by the Investigator

                    -  these may include prolonged (approximately 15 minutes or longer) hemi-clonic
                       seizures

               3. multiple seizure types which may include:

                    -  generalised tonic-clonic (required for inclusion)

                    -  clonic (required for inclusion)

                    -  myoclonic jerks/seizures

               4. history of normal development prior to seizure onset followed by development
                  delay or regression after seizure onset

               5. abnormal EEG consistent with Dravet Syndrome

          2. The patient is currently receiving a stable dose of clobazam of at least 0.5 mg/kg/day
             (maximum 20 mg/day) for at least 3 months

        Other protocol-defined inclusion and exclusion criteria may apply.
Clinical trial NCT02189837 (phase 3, status: completed)
Conditions: primary hyperlipidemia and mixed dyslipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: atorvastatin, placebo to evolocumab, placebo to atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Fasting LDL-C at screening ≥ 100 mg/dL and ≤ 190 mg/dL

          -  Fasting triglycerides ≤ 150 mg/dL

          -  Body mass index (BMI) between 18.0 and 32.0 kg/m^2

          -  Framingham cardiac risk score 10% or less

        Exclusion Criteria:

          -  Treatment with a lipid-regulating drug or over the counter supplement in the last 3
             months prior to screening

          -  History of coronary heart disease (CHD) or CHD equivalent

          -  Uncontrolled hypertension

          -  Diabetes mellitus
Clinical trial NCT02196506 (phase 3, status: completed)
Conditions: depressive disorder, depression, depressive disorder, major, mood disorders, mental disorders
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F32.A, F53.0, P91.4, Z13.31, Z13.32, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F34.81, F39, F34.9, F43.21, F10.14, F10.24, F11.14, F48.9, F99, F51.05, F51.13, F09, F06.8, F48.8
Drugs: placebo + adt, brexpiprazole +adt
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and Female subjects between 18-65 years of age, with diagnosis of major
             depressive disorder with or without anxious distress

          -  Current depressive episode must be at least 8 weeks in duration

        Exclusion Criteria:

          -  Subjects with a history of Neuroleptic Malignant Syndrome or Serotonin Syndrome

          -  Subjects who report an inadequate response to more than 3 antidepressant treatments in
             the current episode

          -  Subjects with a current Axis I diagnosis of: Delirium, dementia, amnestic or other
             cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic
             disorder, Bipolar I or II disorder
Clinical trial NCT02197221 (phase 3, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib-melphalan, melphalan
SMILES: N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have results from their initial diagnosis available at the time of screening to
             confirm all the following :

               1. Diagnosis of multiple myeloma according to the diagnostic

               2. Symptomatic de novo Multiple Myeloma

          -  Be eligible for high-dose therapy with autologous stem cell transplantation

          -  Autologous cell graft with a total number of CD 34 cells > or = 5 X 106/kg before
             freezing

        Exclusion Criteria:

          -  Progressive disease

          -  Females participants pregnant or breast-feeding

          -  A known infection by the human immunodeficiency virus

          -  An active viral hepatitis B or C

          -  Unstable angina or myocardial infarction within 4 months prior to inclusion, heart
             failure NYHA class III or IV angina, uncontrolled, history of severe coronary artery
             disease, an uncontrolled serious ventricular arrhythmia, a sick sinus syndrome, or
             electrocardiographic evidence of acute ischemia or conduction disturbances grade 3
             unless the patient has a pacemaker

          -  Uncontrolled hypertension or uncontrolled diabetes within 14 days before enrollment

          -  A history of another malignancy. If cancer was diagnosed more than 10 years and
             considered as cured, an authorization may be requested on a case-by-case basis after
             discussion with the principal investigator

          -  A significant neuropathy of grade 3-4 or grade 2 with pain in the 14 days prior to
             enrollment
Clinical trial NCT02201459 (phase 3, status: unknown status)
Conditions: chronic myeloid leukemia
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: nilotinib (tasigna ®), capsules of 150 mg, nilotinib (tasigna ®) and pegylated interferon alfa 2a (pegasys®)
SMILES: CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F, CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients

          -  CP-CML, positive Philadelphia chromosome or positive BCR-ABL (M-bcr transcript),
             diagnosed less than 3 months prior to study entry

          -  Age of at least 18 years-old and less than 65 years

          -  Patient for whom treatment with Nilotinib is expected

          -  No other CML treatment except for hydroxyurea and/or anagrelide

          -  No previous TKI treatment.

          -  No previous treatment with IFN even for other purposes.

          -  SGOT and SGPT < 2.5 UNL

          -  Serum creatinine < 2 UNL

          -  No planned allogeneic stem cell transplantation

          -  Signed informed consent

          -  ECOG score 0 to 2

        Exclusion Criteria:

          -  Contra-indication to IFN

          -  Transcripts other than M-Bcr

          -  Pregnancy, lactation

          -  HIV positivity, chronic hepatitis B or C.

          -  Prior or concurrent malignancy other than CML (exceptions to be mentioned)

          -  History of arterial occlusive disease or (peripheral, carotids or severe coronary
             heart disease).

          -  Permanent elevation of total cholesterol and triglycerides despite treatment

          -  Severe psychiatric/neurological disease (previous or ongoing)

          -  Concomitant auto-immune disease

          -  Other investigational product ongoing

          -  Ongoing immunosuppressive treatment

          -  Ongoing treatment at risk for inducing torsades de pointes

          -  QTcF > 450ms despite correction of predisposing factors (i.e electrolytes…)

          -  Congenital long QTcF

          -  Unstabilised thyroid disorder

          -  No health insurance coverage
Clinical trial NCT02201901 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel, rbv
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  HCV RNA > 10^4 IU/mL at screening

          -  Chronic HCV infection (≥ 6 months)

          -  Confirmed CPT class B (7-9) at screening

        Exclusion Criteria:

          -  Current or prior history of solid organ transplantation, significant pulmonary
             disease, significant cardiac disease, or porphyria

          -  Inability to exclude hepatocellular carcinoma (HCC) by imaging within 6 months of
             baseline/Day 1

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Screening ECG with clinically significant abnormalities

          -  Prior exposure to SOF or any other nucleotide analogue HCV nonstructural protein 5B
             (NS5B) inhibitor or any HCV NS5A inhibitor

          -  Laboratory results outside of acceptable ranges at screening
Clinical trial NCT02201940 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel, placebo
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  HCV RNA ≥ 10^4 IU/mL at screening

          -  HCV genotype 1, 2, 4, 5, 6, or indeterminate assessed at screening by the central
             laboratory

          -  Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy

          -  Classification as treatment naive or treatment experienced

          -  Males and females of childbearing potential who engage in heterosexual intercourse
             must agree to use protocol specified method(s) of contraception

        Exclusion Criteria:

          -  Current or prior history of clinically-significant illness (other than HCV) or any
             other major medical disorder that may interfere with treatment, assessment, or
             compliance with the protocol; individuals currently under evaluation for a potentially
             clinically-significant illness (other than HCV) are also excluded.

          -  Screening ECG with clinically significant abnormalities

          -  Laboratory results outside of acceptable ranges at Screening

          -  Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A
             inhibitor

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Clinical trial NCT02201953 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel, sof, rbv
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  HCV RNA ≥ 10^4 IU/mL

          -  HCV genotype 3

          -  Chronic HCV infection (≥ 6 months)

          -  Females of childbearing potential must have a negative serum pregnancy test

          -  Males and females of childbearing potential who engage in heterosexual intercourse
             must agree to use protocol specified method(s) of contraception

        Exclusion Criteria:

          -  Current or prior history of clinically-significant illness (other than HCV) that may
             interfere with subject treatment, assessment or compliance with the protocol

          -  Screening ECG with clinically significant abnormalities

          -  Laboratory results outside of acceptable ranges at Screening

          -  Pregnant or nursing female or male with pregnant female partner

          -  Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease,
             alfa-1 antitrypsin deficiency, cholangitis)

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Clinical trial NCT02203032 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ustekinumab, guselkumab, placebo for ustekinumab, placebo for guselkumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis for at
             least 6 months before the first administration of study drug

          -  Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at
             Screening and at Baseline

          -  Have an Investigator's Global Assessment (IGA) >=3 at Screening and at Baseline

          -  Have an involved body surface area (BSA) >= 10 percent (%) at Screening and at
             Baseline

          -  Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or
             history of previous treatment)

        Exclusion Criteria:

          -  Has a history or current signs or symptoms of severe, progressive, or uncontrolled
             renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
             hematologic, rheumatologic, psychiatric, or metabolic disturbances

          -  Has unstable cardiovascular disease, defined as a recent clinical deterioration
             (example [eg], unstable angina, rapid atrial fibrillation) in the last 3 months or a
             cardiac hospitalization within the last 3 months

          -  Currently has a malignancy or has a history of malignancy within 5 years before
             Screening (with the exception of a nonmelanoma skin cancer that has been adequately
             treated with no evidence of recurrence for at least 3 months before the first study
             drug administration, or cervical carcinoma in situ that has been treated with no
             evidence of recurrence for at least 3 months before the first study drug
             administration)

          -  Has previously received guselkumab or ustekinumab